The newer inherently long-acting dihydropyridine agents (e.g., lacidipine, lercanidipine), which are not currently available in the United States, appear to have comparable efficacy to older ...
[20] At the end of the 12-week trial, the incidence of edema was higher in patients taking amlodipine than in those taking lacidipine. Foot-volume increases occurred significantly more frequently ...